No image available
by Maximilian Klar, Helmut Plett, Philipp Harter, Florian Heitz, Stefan Kommoss, Andreas Daniel Hartkopf, Marcel Grube, Eva Marielouise Roser, Jalid Sehouli, Iona Braicu, Bastian Czogalla, Alexander Burges, Michaela Bossart, Mir Fuad Hasanov, Teresa Link, Annette Staebler, Doris Mayr, Paul Buderath, Annette Hasenburg · 2023
ISBN: Unavailable
Category: Unavailable
Page count: Unavailable
Abstract: Background<br><br>Malignant sex cord-stromal cell tumours (SCST) account for only 7% of ovarian malignancies. The Arbeitsgemeinschaft fuer Gynaekologische Onkologie (AGO) study group has established a clinicopathological database to provide an overview of the current treatment strategies and survival of SCST patients and to identify research needs.<br>Methods<br><br>Twenty centres provided mixed retro- and prospective data of patients with tumour specimens and second-opinion pathology review treated between 2000 and 2014. Descriptive analyses of treatment strategies, Kaplan-Meier curves and cox regression analyses were conducted.<br>Results<br><br>Two hundred and sixty-two SCST patients were included. One hundred and ninety-one Granulosa-cell tumour (GCT) and 17 Sertoli-Leydig cell tumour (SLCT) patients were stage I disease (>80%). Forty four GCT (18.7%) and two (8.3%) SLCT patients received adjuvant systemic treatment. After a median observation time of 78.2 months, 46% of all SCST patients experienced disease recurrence, treated predominantly with secondary debulking surgery (> 90%). Advanced FIGO stage, lymph node involvement and intra-operative capsule rupture were associated with disease recurrence on univariate analysis (all p 0.05). Median OS time was not reached.brDiscussionbr